Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · mng-umap@100

MNG1130

—

9b609501-f34a-55a8-91f0-661d470d77ab

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.459
  • ANGIOGENESIS+0.311
  • PANCREAS_BETA_CELLS+0.286
  • MYC_TARGETS_V1+0.284
  • MTORC1_SIGNALING+0.279
  • OXIDATIVE_PHOSPHORYLATION+0.272
  • ALLOGRAFT_REJECTION+0.249
  • COAGULATION+0.245
  • E2F_TARGETS+0.245
  • MYC_TARGETS_V2+0.197

Top 10 suppressed

  • TNFA_SIGNALING_VIA_NFKB-0.301
  • MITOTIC_SPINDLE-0.220
  • BILE_ACID_METABOLISM-0.209
  • PEROXISOME-0.192
  • TGF_BETA_SIGNALING-0.175
  • ESTROGEN_RESPONSE_EARLY-0.172
  • HEME_METABOLISM-0.149
  • CHOLESTEROL_HOMEOSTASIS-0.148
  • ESTROGEN_RESPONSE_LATE-0.143
  • P53_PATHWAY-0.129

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

8 twins match this tumor's tissue · 2 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR33532784
breast-umap@18
—A0.692
2SRR12202482
bladder-landscape@3
——0.683
3R95
bladder-landscape@3
——0.676
4SRR33532779
breast-umap@18
—A0.647
5TCGA-85-8276-01A-11R-2296-07
lung-landscapes@6
—cohortSQ10.630
6SJEPD032407_D2.RNA-Seq
medullo-epn-umap@date-based
EPNAnaplastic EPN0.623
7SRR1313137
breast-umap@18
—E0.623
8MNG952
mng-umap@100
——0.622
9MDT-AP-2494
medullo-epn-umap@date-based
MedMedulloblastoma0.614
10MBCProject_0852_T2_RNA
breast-umap@18
—E0.609

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 28 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
EPITHELIAL_MESENCHYMAL_TRANSITION0.459Inavolisib— uncovered
ANGIOGENESIS0.311Remibrutinib— uncovered
PANCREAS_BETA_CELLS0.286Cobimetinib— uncovered
MYC_TARGETS_V10.284Inavolisib— uncovered
MTORC1_SIGNALING0.279Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.272Remibrutinib— uncovered
ALLOGRAFT_REJECTION0.249Idelalisib— uncovered
COAGULATION0.245Binimetinib— uncovered
E2F_TARGETS0.245Inavolisib— uncovered
MYC_TARGETS_V20.197Idelalisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.161Idelalisib— uncovered
G2M_CHECKPOINT0.134Inavolisib— uncovered
APICAL_SURFACE0.125Temsirolimus— uncovered
SPERMATOGENESIS0.109Inavolisib— uncovered
MYOGENESIS0.095Inavolisib— uncovered
UV_RESPONSE_DN0.089Inavolisib— uncovered
GLYCOLYSIS0.084Inavolisib— uncovered
IL2_STAT5_SIGNALING0.080Idelalisib— uncovered
KRAS_SIGNALING_UP0.075Inavolisib— uncovered
WNT_BETA_CATENIN_SIGNALING0.066Inavolisib— uncovered